StockData

DBV Technologies vs Eloxx Pharmaceuticals

DBVT and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DBVT and ELOX compare

DBV Technologies is the larger company, worth 69 times as much as Eloxx Pharmaceuticals ($3.6B against $52.5M).

DBV Technologies grew revenue faster over the last twelve months (−31.6% versus −100% for Eloxx Pharmaceuticals).

Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 6 for DBV Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDBVTELOX
Size and price
Market cap$3.6B$52.5M
Share price$11.51$13.01
Change, 1 year−17.6%1182630%
Change, 5 years88.1%−97.8%
Beta (5Y)0.58–
Employees1257
StockData Score
Total score67 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S943×–
P/B24.4×1.1× (better)
FCF yield−5.3%–
Growth
Revenue growth (TTM)−31.6% (better)−100%
Revenue growth, 5Y average−13.0%–
Profitability
Operating margin−5432%–
Net margin−5405%–
FCF margin−4998%–
Return on equity−206%−54.3% (better)
Financial health
Debt / equity0.000.00
Current ratio3.243.74 (better)
Altman Z-score27.93 (better)−4.42
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions6.8%71.8%
Held by insiders12.1%42.6%
Insider net buying, 12 months−$15.5M–
Superinvestors holding1–
Short interest, % of float–2.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.